AU2020352528A1 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors - Google Patents

Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors Download PDF

Info

Publication number
AU2020352528A1
AU2020352528A1 AU2020352528A AU2020352528A AU2020352528A1 AU 2020352528 A1 AU2020352528 A1 AU 2020352528A1 AU 2020352528 A AU2020352528 A AU 2020352528A AU 2020352528 A AU2020352528 A AU 2020352528A AU 2020352528 A1 AU2020352528 A1 AU 2020352528A1
Authority
AU
Australia
Prior art keywords
formula
cancer
egfr
hydrogen
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020352528A
Other languages
English (en)
Inventor
Michael John COSTANZO
Michael Nicholas Greco
Michael Alan Green
Jirong Peng
Don Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of AU2020352528A1 publication Critical patent/AU2020352528A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020352528A 2019-09-23 2020-09-23 Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors Pending AU2020352528A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962904567P 2019-09-23 2019-09-23
US62/904,567 2019-09-23
PCT/US2020/052096 WO2021061695A1 (en) 2019-09-23 2020-09-23 Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors

Publications (1)

Publication Number Publication Date
AU2020352528A1 true AU2020352528A1 (en) 2022-04-21

Family

ID=75166417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020352528A Pending AU2020352528A1 (en) 2019-09-23 2020-09-23 Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors

Country Status (7)

Country Link
US (1) US12390464B2 (https=)
EP (1) EP4034121A4 (https=)
JP (1) JP2022549272A (https=)
CN (1) CN114430681A (https=)
AU (1) AU2020352528A1 (https=)
TW (1) TW202126305A (https=)
WO (1) WO2021061695A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954298A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6709786B2 (ja) * 2014-12-11 2020-06-17 ベータ ファーマ，インコーポレイテッド Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
US20190275049A1 (en) * 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS

Also Published As

Publication number Publication date
US12390464B2 (en) 2025-08-19
WO2021061695A1 (en) 2021-04-01
TW202126305A (zh) 2021-07-16
US20220347177A1 (en) 2022-11-03
JP2022549272A (ja) 2022-11-24
EP4034121A4 (en) 2023-10-18
CN114430681A (zh) 2022-05-03
EP4034121A1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
KR102772574B1 (ko) 키랄 디아릴 매크로사이클 및 이것의 용도
US20210030758A1 (en) Treatment of cancers having driving oncogenic mutations
WO2025067459A2 (en) Therapies for the treatment of cancer
KR20220148847A (ko) 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
SG194047A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
KR20230008719A (ko) Tno155 및 나자르티닙을 포함하는 약제학적 조합물
TW201529071A (zh) 癌症治療組合療法
KR20200135743A (ko) 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
US12390464B2 (en) Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors
CA3113408A1 (en) Cancer combination therapy using quinoline carboxamide derivative
WO2014031856A1 (en) Combination therapy using pi3 kinase and braf inhibitors
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
WO2025188239A1 (en) Pan-tead inhibitors and methods thereof
WO2026064479A1 (en) Cdk2 inhibitor for the treatment of kras mutant cancer
CN121013721A (zh) 包含kras抑制剂和sph2抑制剂的组合疗法
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法